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Die vorliegende Arbeit stellt die Ergebnisse der operativen Behandlung von Patienten mit 
renalem Hyperparathyroidismus (HPT) nach einer präoperativen Therapie mit Cinacalcet vor. 
Diese sind in Form einer retrospektiven Studie untersucht. 
Der renal HPT ist eine der späten Komplikationen der fortgeschrittenen Niereninsuffizienz und 
erhöht die Morbidität von diesen Patienten. Die Nierentransplantation führt nicht immer zur 
Heilung des renalen HPT. Ausdruck dieser hormonellen Störung ist die renale Osteopathie, 
steigende kardiovaskuläre Morbidität und Mortalität, Nierentransplantatdysfunktion. 
Der renal HPT wird konservativ mit Vitamin D und Phosphatbindern behandelt, zudem ist seit 
2004 eine Targettherapie mit Cinacalcet, allosterischer Modulator der Ca-sensing Rezeptoren, 
verfügbar. Die konservative Behandlung kann den renalen HPT über einen Zeitraum 
kontrollieren. Wenn das Versagen der medikamentösen Therapie auftritt, bleibt die chirurgische 
Behandlung die einzelne Option. Es werden subtotale, totale Parathyreoidektomie (mit oder ohne 
Autotransplantation) durchgeführt, mehrere Studien haben diese Operationen als effektive 
Behandlung belegt. Keine Studie hat die Ergebnisse der operativen Behandlung bei Patienten 
unter Cinacalcetbehandlung untersucht. 
Die vorliegende Studie mit 191 Patienten im Zeitraum 2008-2015 analysiert die Ergebnisse der 
chirurgischen Therapie der Patienten im Charité Campus Virchow Klinikum. Die Studie 
fokussierte sich auf den Vergleich von Patientengruppen mit und ohne präoperativer 
Cinacalcetbehandlung. Cinacalcet wurde durch niedergelassenen Nephrologen verordnet, diese 
Entscheidung war von den Chirurgen an der Charité unabhängig. Die weitere medikamentöse 
Therapie unterscheidet sich im Wesentlichen nicht, sowie die demographische Patientendaten, 
Komorbiditäten etc. 
Daten zu der operativen Behandlung wurden analysiert: Operative Effektivität, Komplikationen, 
Rezidivrate. Im frühen postoperativen Verlauf wurden die Calcium und Parathormon von 
besonderem Interesse. 
Wir verfügten über die Laborwerte in jährlichen Abständen nach der Operation. Daten über 
Nierentransplantation und Graftfunktion, kardiovaskulären Ereignissen und Mortalität, 
Osteopatie und Auftreten einer Hypoparathyroidismus oder eines Rezidivs des HPT wurden 
erhoben. 
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Es gab keine signifikanten Unterschiede in den unmittelbaren Operationsergebnissen 
(Effektivität) und Komplikationsraten zwischen den Studiengruppen. Präoperativer Serum-Ca 
war in der Gruppe mit Cinacalcet signifikant niedriger, 2.28±0.23 vs. 2.41±0.23 mmol/l 
(p=0.0002), was die Therapieeffektivität beweist. 
Die aktuelle Studie ist die erste publizierte Analyse der chirurgischen Therapie der renalen HPT, 
die sich auf Effekte der präoperativen Cinacalcetbehandlung fokussiert. Es wurden keine 
signifikanten Unterschiede in Effektivität sowie Sicherheit der operativen Behandlung zwischen 
Patienten mit und ohne Cinacalcet gesehen. Rate der Blutungen, Nervenparesis, Infektionen, 
kardiovaskulären Komplikationen, postoperative Hypokalziämie wiesen keinen 
Gruppenunterschied auf. 
Die chirurgische Behandlung stellte sich in der Studiengruppe trotz teils multimorbider Patienten 
als eine sichere Option dar. 
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2.  Conclusion. 
This retrospective cohort study presents the results of surgical therapy in patients with renal 
hyperparathyroidism (HPT) receiving cinacalcet preoperatively. 
Renal HPT is a late complication of chronic kidney disease; it worsens the prognosis in this 
predominantly multimorbid group of patients. Renal HPT doesn’t always resolve after renal 
transplantation. Renal osteopathy, cardiovascular complications and mortality, impairment of 
renal graft function are the main outcomes of renal HPT. 
Modern therapy of renal HPT consists of active forms of Vitamin D and phosphate binders; since 
2004 is a target therapy with cinacalcet, an allosteric modulator of calcium sensing receptor, 
available. The renal HPT can be effectively pharmacologically treated over a period of time. An 
operation is the only option after the failure of medical treatment. Subtotal and total 
parathyroidectomy (with or without autotransplantation) are performed, and the outcomes of all 
types of operations analyzed in many retrospective studies have shown their comparable 
effectiveness. There are no studies comparing the surgical outcomes in patients relative to 
cinacalcet therapy. 
Current study included 191 patients operated in 2008-2015 in Charité Campus Virchow 
Klinikum. The study was aimed at comparison of patients with and without cinacalcet 
preoperatively. Cinacalcet was prescribed by the attending nephrologists and the surgical team 
had no influence on that decision. The remaining medical therapy did not differ significantly 
between the study groups, neither there were differences in demographic data, overall morbidity 
etc. 
Outcomes of surgical treatment studied included efficacy, complication rate, rate of recurrence. 
Laboratory values – serum calcium and parathyroid hormone were of higher interest in the first 
days after operation. 
Our study provided yearly controls of laboratory values. Renal transplantation status and data on 
graft function, cardiovascular morbidity and mortality, renal osteopathy, signs and symptoms of 
hypoparathyroidism, and recurrence of hyperparathyroidism were analyzed. 
The efficacy of surgical treatment was similar in both groups, as was the rate of complications. 
Preoperative serum Ca was significantly lower in the cinacalcet group, 2.28±0.23 vs. 2.41±0.23 
mmol/l (p=0.0002), confirming the existing treatment effect. 
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Actual study is the first to compare the results of surgical treatment of renal HPT with focus on 
preoperative cinacalcet therapy. Efficacy and safety of the surgical treatment was proved to be 
similar in both groups. There was no difference in rates of bleeding, nerve palsy, infections, 
cardiovascular complications and postoperative hypocalcemia. 





Small things often go unnoticed. This is applicable to the parathyroid glands. Even today in spite 
of new developments in medicine, diseases associated with these glands are difficult to diagnose 
and cure [1]. 
Parathyroid surgery became effective only when the role of parathyroid glands in bone and 
mineral metabolism disorders was described. Though the anatomical description of parathyroid 
glands was made in 1850´s, only in the 20th century, due to hormonal assessment and visual 
diagnostic methods, adequate treatment became possible. However many fundamental questions 
still remain unsolved [2]. 
4. Parathyroid glands 
4.1.  History 
In 1850 Sir Richard Owen (an anatomist and curator of the Natural History Museum in London) 
was the first to describe the parathyroid glands as he dissected a rhinoceros that died in the 
London Zoo. That time he made no histological confirmation. In 1887 a Swedish medical 
student, Ivar Sandstrom, described new glands in 50 dissected human bodies and called them 
“glandula parathyroideae”. He gave their full anatomical description [1]. The physiology of 
parathyroid glands, namely the relation between parathyroid gland function and tetany, was 
clarified by the French Physiologist Eugene Gley in his experiments on rats and rabbits. He 
showed that the removal of parathyroid gland performed either with or without thyroidectomy 
invariably caused tetany in both cases [1]. 
In 1920´s parathyroid hormone (PTH) was described as the most important calcium(Ca) 
regulating hormone that was produced by the parathyroid gland [3]. Since that time many 
investigators had used parathyroid gland extract to treat postoperative tetany in animal 
experiments. It was shown that those extracts were able to cure tetany and to raise serum Ca as 
well as to induce osteoporosis when administered over a prolonged period [1]. 
The first parathyroidectomy (PTx) performed by Felix Mandel in Wien opened the era of 
surgical treatment of hyperparathyroidism (HPT). He operated on a man with ‘osteitis fibrosa 
cystica’ - the result of primary hyperparathyroidism (pHPT) [4]. Nowadays, with the 
development of long-time substitution therapy and renal transplantation surgery caused by the 
rising number of chronic kidney diseases (CKD) leading to renal failure, the number of patients 
with renal HPT has substantially increased [1]. 
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In 1959, due to contemporary technologies, Aurbach G.D., Rasmussen H. and Craig J.C. 
isolated, purified and determined the structure of PTH [3]. The desoxyribonucleic acid (DNA) 
sequence of the PTH gene was identified in 1977. In 1993 Edward M. Brown et al. cloned and 
structurally characterized the parathyroid calcium-sensing receptor (CaSR) [5]. Advances in the 
field of parathyroid studies have led to the introduction of new drug substances and progress in 




Figure 1: The frequency of locations (in percents) of superior (A) and inferior (B) parathyroid 
glands from «Endocrine Surgery» by A.Schwartz et al. [6]. 
Parathyroid glands, usually four, are located on the posterior surface of the thyroid gland each in 
a separate connective tissue capsule. Alternatively, parathyroid glands can be localized in the 
thyroid gland capsule, and in thyroid gland tissue. Other ectopic sites are the carotid bifurcation 
region and the upper mediastinum often in the thymus. Some individuals have supernumeric 
parathyroid glands (normally 5), others only have three glands [7].  
Studies report 5-16.5% of supernumeric glands in surgically removed tissue, in 5.7% of cases 
only three parathyroid glands were found [8-10]. In a classical 1984 autopsy study of 503 non-
hyperparathyreotic patients, the rate of supernumeric glands was 13%, whereas in 3% of 
Location of superior parathyroid glands Location of inferior parathyroid glands 
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dissected cadavers only three parathyroid glands were found [11]. The rate of ectopic glands was 
as large as 19% [10]. 
Blood supply to the parathyroid glands normally comes from the inferior thyroid artery, blood 
supply to ectopic glands varies respectively to their localization [7]. 
4.3. Physiology/Pathophysiology 
Parathyroid glands regulate mineral metabolism through secreting PTH, as demonstrated on the 




Figure 2: Schematic representation of hormonal control loop, from Harrison Endocrinology [12]. 
Legend: 25(OH)D3- 25-Hydroxyvitamin D; Pi – phosphate; 1,25(OH)2D3 - 25-Dihydroxyvitamin 
D; PTH – parathyroid hormone. 
The metabolic functions of PTH in regulating serum Ca levels can be summarized as follows: it 
increases the renal tubular reabsorption of Ca, thereby conserving free Ca; it increases the 
conversion of vitamin D to its active dihydroxyform in kidneys. PTH increases urinary 
phosphate excretion, thereby lowering serum phosphate levels. PTH augments gastrointestinal 
Ca absorption (figure 2) [13]. 
The kinetic analysis of PTH shows an extremely short half-life time in peripheral blood, 
approximately four minutes [14]. 
In normal conditions parathyroid glands have a very low rate of mitosis in an adult human [2]. 
Under specific conditions, such as hypocalcemia, hyperphosphatemia and uremia, parathyroid 
glands first show cell hypertrophy, and then begin to proliferate, which ends in autonomous 
monoclonal cell growth [13]. The process of regress or apoptosis of these cells is not described, 
even when the initial triggering factor is removed [2]. 
5. Primary hyperparathyroidism 
PHPT is a relatively common condition, mostly diagnosed through abnormally elevated serum 
Ca levels. Clinical findings in pHPT include bone disease, nephrolithiasis, gastrointestinal 
disturbances, central nervous system alterations, neuromuscular abnormalities, aortic and heart 
valve calcifications. The course of the disease is asymptomatic in many cases. In 85-90% of 
these cases a solitary adenoma is found in a previously normal parathyroid gland. Diffuse 
hyperplasia associated with hereditary syndromes is found in 5 to 20% of patients with pHPT: 
multiple endocrine neoplasia-1 (MEN-1), MEN-2, familial hypercalciuric hypercalcemia and 
hyperparathyroidism-Jaw tumor syndrome. Parathyroid cancer is a very rare disease, app. less 
than 1% of pHPT cases [2, 13]. 
6. Hyperparathyroidism in renal insufficiency 
6.1. Pathophysiology 
Renal, or secondary HPT (renal HPT, or sHPT) is detected even in the early stages of CKD, 
progressing with the level of renal insufficiency. All patients on haemodialysis have renal HPT 
[15]. 
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The mechanisms by which chronic renal failure induces sHPT are complex and not fully 
understood. A decrease in serum Ca, excess of serum phosphate and low 1,25(OH)2D3 level play 
the leading role here [6]. 
Ca binding to CaSR suppresses PTH production, and hypocalcemia is a stimulating factor for 
PTH production because of the reciprocal character of this interaction [5]. 
Chronic renal insufficiency is associated with decreased phosphorus (P) excretion, which in turn 
results in hyperphosphatemia. Elevated serum P levels directly depress serum Ca levels and 
thereby stimulate parathyroid gland activity [15]. 
In addition, the loss of renal substance reduces the availability of α-1-hydroxylase necessary for 
the synthesis of the active form of vitamin D3, which suppresses PTH synthesis by binding to the 
vitamin D receptor (VDR). Low 1,25(OH)2D3 levels also reduce intestinal absorption of Ca [12]. 
Another factor suppressing PTH synthesis is fibroblast growth factor-23 (FGF23) which acts 
binding to its receptor, FGFR. FGF23 modulates P/vitamin D3 interaction, and its serum level is 
elevated in CKD patients [13, 16]. 
Parathyroid activity may become autonomous and excessive, with resultant hypercalcemia, a 
process that is sometimes termed “tertiary hyperparathyroidism”.  The synonymous term 
“autonomous hyperparathyroidism” describes the missing feedback mechanism more accurately 
[13]. 
6.2. Clinical features of renal HPT 
Common clinical presentations of renal HPT are bone pain, ectopic calcification and pruritus.  
CKD-Mineral and Bone Disorder (CKD-MBD) describe all clinical abnormalities of mineral and 
bone metabolism associated with CKD [17]. Renal osteodystrophy is a term used to describe 
bone disease in patients with chronic renal failure. It is characterized by such parameters as 
turnover, mineralization and volume [18]. There are several types of renal osteodystrophy 
according to the American Society for Bone and Mineral Research classification, and the golden 
standard to diagnose it is a bone biopsy [1]. Osteitis fibrosis cystica is the most common disorder 
(over 40%) characterized by high-turnover dystrophy due to high PTH levels. Adynamic 
(aplastic) bone disease is found in up to 40% of patients and is a low-turnover dystrophy. Low 
PTH levels (<100pg/ml) in renal HPT patients are highly predictable for the development of 
adynamic bone disease. A mixed type of bone dystrophy is found in appr. 20% of patients. 
Contemporary studies show a low incidence of osteomalacia due to broad use of vitamin D3 
analogues. Aluminium deposition in bones used to cause an osteomalacia-like picture in X-ray 
studies, nowadays this pathology is rare due to non-aluminium based phosphate binders and 
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thorough water treatment in dialysis [12]. Histological confirmation is not available in most 
cases because the procedure of bone biopsy is expensive and invasive. In clinical practice serum 
PTH levels are used as an indirect indicator of bone disease [12]. 
CKD-associated pruritus is frequent in patients with end-stage renal disease. Many of them 
suffer from generalized pruritus that has negative influence on patient´s quality of life. Effective 
treatment options are limited because of unclear pahtophysiological mechanisms [19]. 
The disturbances of Ca-P homeostasis, misbalance of other regulatory factors – FGF23, CaSR 
expression, osteo/chondrogenic differentiation, vesicle release, apoptosis and loss of inhibitors, 
and degradation of extracellular matrix in CKD patients are associated with a higher rate of 
vascular calcification [20]. 
Vascular calcification of the coronary arteries, aortic branches, renal and peripheral arteries is 
manifested in patients with CKD III, and is associated with a high risk of cardiovascular events 
and mortality from cardiovascular diseases [21]. According to pathological studies, the 
prevalence of mortality due to cardiovascular events was over 50% in patients with CKD V [22]. 
If HPT persists after kidney transplantation (KTx), graft vessel calcification can be detected as 
soon as six months after the KTx. HPT also correlates with inferior graft function [23]. 
Other HPT associated symptoms are depression and non-specific psychological distress, leading 
to decreased quality of life [24, 25]. 
6.3. Epidemiology 
There are app. 70.000 patients with terminal CKD in Germany as to 2009, according to DGfN 
statistics (Deutsche Gesellschaft für Nephrologie), the prevalence is 17.5/100,000 in the local 
population [26]. 
In the 1991 pan-European report on CKD statistics,  parathyroidectomy (PTx) was indicated in 
15% of patients 10 years after the start of chronic dialysis and in 38% of patients after 20 years 
of dialysis [27]. The annual incidence of renal HPT was estimated at 0.7-1.4% in the late 1990-s 
according to the literature review by F.Triponez et al. [28]. 
In the International population study DOPPS, a decline in the rate of PTx was stated (starting 
from study Phase 3, 2005-2008), after cinacalcet with active vitamin D3 analogues became 
available for the conservative treatment of renal HPT [29]. 
6.4. Indication for surgical treatment 
Despite expensive therapy with active Vitamin D3 analogues, phosphate binders and 
calcimimetics, surgical treatment will be indicated for up to 32% of patients with renal HPT [30]. 
Even after KTx, an ultimate method of restoring bone-mineral metabolism,  0.6-5.6% of patients 
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will require a parathyroidectomy according to a review by P. Evenepoel et al. [31]. There is a 
direct correlation between the need for parathyroid surgery in transplanted patients and the 
duration of dialysis before KTx [32], as well as parathyroid gland size on ultrasound [33]. 
Indications for the operations are given in tight cooperation between surgeons and nephrologists. 
A cost-effectiveness analysis has shown, that an early surgical treatment in patients meeting the 
K/DOQI (Kidney Disease Outcomes Quality Initiative) criteria is favourable compared to a 
prolonged medical therapy [34]. Patients with a high ASA score (American society of 
Anesthesiology), high risk of perioperative complications, persistent or recurrent HPT are 
subjects for discussion [30]. 
6.5. Medical treatment 
Conservative treatment of renal HPT consists of dietary phosphate restriction, the use of 
phosphate binders, correction of hypocalcemia during the dialysis, and application of vitamin D3 
sterols [17]. 
Even the use of non-Ca based phosphate binders (sevelamer hydrochloride, lanthan-based) and 
active vitamin D3 analogues does not always lead to the regression of Ca, Ca-P product, and 
PTH to target levels [35]. 
Fundamental studies of mineral metabolism regulation have led to the development of targeted 
therapy with precise action on a molecular level. Substances selectively binding to CaSR and so 
downregulating the secretion of PTH are called calcilytics but they have never been used in 
clinical practice. Calcimimetics, drugs modulating the CaSR, represent a drug group with similar 
action and have shown clinical efficacy [36]. 
6.6. Surgical treatment 
The K/DOQI 2003 guidelines state in §14 that parathyroidectomy is indicated in patients with 
severe HPT (intact PTH>800 ng/l in serum) associated with hypercalcemia, hyperphosphatemia 




Indication for parathyroidectomy in renal HPT 
 Hypercalcemia: 
o Spontaneous 
o Induced by medical treatment 
o Persistent (1 year) even after 
KTx 
 Severe renal osteopathy (x-ray or 
histological confirmation required) 
 Vascular calcifications or soft tissue 
calcifications* 
 Calciphylaxis* 
 Hyperphosphatemia*, resistent to medical 
treatment 
 Pruritis*, resistent to medical treatment 
*supplementary criteria: 
-when PTH>800 pg/ml (>88 pmol/l) and no 
effect of medical treatment, 
-when PTH>100 and <800 pg/ml, an adynamic 
bone disease should be excluded 
Contraindication for operation is PTH <100 
pg/ml which stands for adynamic bone disease 
Table 1: Indications for parathyroidectomy in renal HPT from C.Dotzenrath, 2010 [37]. 
According to K/DOQI guidelines, the three operative procedures - total PTx (tPTx), subtotal PTx 
(sPTx), and total PTx with autotransplantation (tPTx with AT) - are equally effective in view of 
the outcome [34]. 
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Figure 3: Intraoperative view of enlarged parathyroid glands in a patient with renal HPT, 
visualized from one side (Picture’s ownership: Prof. N.Rayes, Charité hospital, 2015). 
PTH does not always decrease following KTx [28, 38]. In transplanted patients with severe 
tertiary HPT (tHPT) a temporary postoperative hypoparathyroidism after PTx could comprise 
graft function. For this reason PTx prior to KTx is favourable [32, 38]. 
Indication for PTx after successful KTx are: 
a) persistent hypercalcemia that doesn’t resolve under medical treatment, and 
b) symptomatic HPT defined as graft calcification, renal osteopathy, soft tissue calcifications, 
muscle or bone pain [38]. 
Surgical treatment modalities are subtotal parathyroidectomy and total parathyroidectomy. Total 
parathyroidectomy can be performed with or without autotransplantation (AT) of parathyroid 
tissue into the upper limb muscle. Both operations are listed as standard treatment in the actual 
2003 K/DOQI guidelines [34]. 
All four parathyroid glands are to be identified during the operation. When a gland is missing, 
the fat tissue on the caudal thyroid gland poles should be explored; additionally a cervical 
thymectomy should be performed. Routine cervical thymectomy is recommended if preoperative 
imaging with ultrasound or scintigraphy with 99-Technecium sestamibi (99mTc) has shown an 
ectopic parathyroid gland in the thymus [6]. 
Cryopreservation of parathyroid tissue is a method allowing a delayed AT, an operation known 
for over 30 years. Effectiveness of AT (rate of graft function) is estimated at 60% [39], at the 
same time the need for this procedure is low, as reported in a large retrospective study, 
13/606=2.1% [40]. 
• SPTx consists of removing 3 ½ - 3/4 of parathyroid glands. The remaining minimal part 
of the parathyroid gland is marked with a non-resorbable suture or with a clip. The advantage of 
this operation is short duration and no need for cryopreservation (not available in some clinics) 
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and low risk of postoperative hypoparathyroidism. At the same time, defining an adequate blood 
supply of the remaining tissue is technically challenging, as are the reoperations in case of 
recurrent HPT in the neck [6]. 
• In tPTx with AT all four PT glands are removed. A small part of the visually least 
structurally altered parathyroid gland is sliced and a part of it is transplanted into the forearm 
muscle of the non-shunt bearing arm. The advantage is a very low reoperation rate on the neck 
for recurrent disease. Disadvantages are a higher rate of postoperative hypoparathyroidism (the 
transplanted auto-tissue starts to function after an average of few months) and a relatively higher 
rate of overall HPT recurrences. An additional possible source of recurrent HPT is hyperfunction 
of the transplanted tissue in the forearm. Once the renal insufficiency with hyperphosphatemia 
and hypocalcemia are persisting, the transplanted PTG tissue may proliferate as well 
necessitating a surgical removal [6].  
• TPTx, removal of all PT glands without AT, is an operation of choice in older patients 
and when no KTx is planned. This operation offers low to zero recurrence rates if no ectopic 
glands were overlooked. A cryopreservation of parathyroid tissue is an option allowing a delayed 
AT in cases of otherwise uncontrollable hypoparathyroidism [6, 41]. 
According to the analysis of questionnaires sent to hundreds of clinics, one of these three 
operations was reported as a standard procedure in the vast majority of nephrological centers all 
over the world. [42]. The results of the survey showed the rarity of other types of surgical 
interventions. 
The debates about the preference of sPTx or tPTx with AT are still ongoing in literature [28, 40, 
42-44]. In a meta-analysis by Richards et al. [43] 51 studies of recurrent and persistent HPT after 
sPTx versus tPTx + AT were analyzed. A higher rate of recurrences was recorded in the total 
PTx + AT group, namely the cases of recurrent disease in the forearm graft. 
This finding was confirmed in a retrospective study by C. Dotzenrath et al. [44], where a cohort 
of 303 patients with 9% of reoperations (5.8% for recurrent ad 3.1% for persistent disease) was 
analyzed. There was no recurrent disease in the neck in the sPTx group when 3½ glands were 
removed, i.e. there was no hyperfunction in the remnant in the neck, as opposed to 6% (5/99) 
rate of graft hyperfunction in the forearm. 
In a meta-analysis of 41 studies, the transitory hypocalcemia rate was 0 to 10% after sPTx and 
up to 100% in tPTx with/without AT. The analyzed studies have shown that the autotransplanted 
tissue begins to function a few months after the operation. A persistent hypoparathyroidism was 
noticed in 0 to 10% of cases, with a higher prevalence in the tPTx + AT group. Considering a 
high rate of hypoparathyroidism the authors recommended a sPTx in patients after KTx [28]. 
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Schneider et al. examined long-term outcomes in patients who underwent KTx after any of the 
three above mentioned types of PTx – none of the patients required a delayed AT of parathyroid 
tissue, neither were there clinical presentations of adynamic bone disease (specific markers were 
not tested). The existing data on the risk of adynamic bone disease did not allow the authors to 
recommend a tPTx as a standard procedure [40]. Other contemporary studies do not report the 
development of adynamic bone disease either. [45, 46]. 
6.7. Surgical complications 
Most complications in parathyroid surgery are similar to those in thyroid surgery [7]: 
Complication type Complication rate Source 










[38, 40, 46] 
[38, 40, 46] 
neck hematoma and wound 
infection 
0-3.1% [40, 46] 
transient postoperative 
hypocalcemia 
˂ 10% [28] 
Table 2: Rates of complications in parathyroid surgery 
Specific rare surgical complications are injury of the superior laryngeal nerve, vagus nerve, 
intraoperative vascular injury and injury of neighboring organs (trachea, esophagus) [7]. 
Technical complications listed above have falling numbers in experienced surgical teams, and 
the postoperative hypocalcemia is well controlled by existing protocols of Ca substitution and 
vitamin D3 analogues [6]. 
The one specific complication is persistent HPT or recurrent HPT. If the PTH level drops to 
normal values after the operation and rises afterwards, it is defined as a recurrent HPT. If there is 
no drop of PTH after the operation, it is defined as a persistent HPT. This concept is nowadays 
widely accepted in the professional community [17]. 
Persistent HPT may result from the failure in finding a parathyroid gland when it is ectopic or 
supernumerary [7]. It may also be a result of functionally active parathyroid tissue, intentionally 
left during sPTx or autotransplanted into the forearm muscle when the driving factors of renal 
insufficiency are present [41]. In these conditions the hormonal activity of parathyroid tissue 
(typically in thymus), may become clinically significant [47]. 
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Despite the multimorbidity of the patients undergoing this special type of operations, a thorough 
preoperative selection of patients and adequate operative techniques lead to very low 
perioperative mortality rates [48]. 
7. Cinacalcet 
7.1. Mode of action 
Cinacalcet hydrochloride is a positive allosteric modulator of the cell surface CaSR. Activation 
of CaSR inhibits the PTH secretion, stimulates the calcitonin secretion and lowers the Ca level in 
serum [49]. Currently cinacalcet is the only calcimimetic drug available on the market; it is a 
second generation substance of this class [50]. 
 
Figure 4: Action mode of calcimimetics. The images on the left and in the middle represent a 
physiologic response of parathyroid cells to high and low Ca levels. In a hypocalcemic state 
(right image) the CaSR may be activated through allosteric binding and a hypersecretion of PTH 
is thus avoided [51]. 
Other drugs from the group of calcimimetics are currently being tested, with alternative effect 
profiles, for example reducing PTH but not causing hypocalcemia in patients with CKD III-IV. 
An example of an emerging new calcimimetic is AMG416, velcalcetide [50, 52]. 
7.2. Clinical studies 
In 2002 the corporation Amgen has synthesized cinacalcet [49]. Cinacalcet became 
commercially available for use in the US in May 2004 [53]. 
Multiple studies, ACHIEVE [35], ECHO [54], OPTIMA [55] and others were performed to 
define the properties and efficacy of the new drug. 
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ECHO was a pan-European study with observational design where patients with rHPT were 
included, both those with previous PTx and without it. The investigators focused the study on 
controlling the biochemical parameters as defined by K/DOQI. Cinacalcet has shown positive 
results in that the serum Ca, P, PTH levels were within K/DOQI treatment goals in most patients. 
There was no detailed report on the type of PTx operations performed [54]. 
In the US multicenter open-label randomized controlled ACHIEVE study cinacalcet + low-dose 
Vitamin D3 was compared with flexible Vitamin D3 therapy. The cinacalcet-treated patients have 
shown better therapy response according to K/DOQI treatment goals, and in a small proportion 
of these patients all four parameters decreased to reference ranges (Ca, P, Ca x P product, PTH) 
[35].  
OPTIMA was a pan-European multicenter open-label randomized controlled study comparing 
cinacalcet-based therapy with conventional therapy with Vitamin D3 analogues. The results were 
favourable for cinacalcet. Patients who were not responding to conventional therapy were more 
likely to achieve K/DOQI recommended target biochemical parameters on cinacalcet-based 
therapy [55]. 
In a 2016 meta-analysis patient-important outcomes in 24 published trials were reviewed. 
Patients receiving cinacalcet had significantly smaller number of parathyroidectomies 
performed, compared to standard therapy. There was no difference in mortality between the 
study arms [56]. 
Cinacalcet has shown to reduce PTH levels in patients with and without nodular hyperplasia and 
to reduce the volume of parathyroid gland measured with ultrasound [57, 58]. Another Japanese 
study has shown a reduction in serum PTH levels in patients either with or without nodular 
hyperplasia; however the reduction in parathyroid gland volume could not be confirmed [59]. 
Reviewing the study outcomes, Stubbs et al. [16] conclude that cinacalcet combined with 
1,25(OH)2D3 improves the overall CKD prognosis. It reduces the cardiovascular morbidity and 
mortality through multiple effects on RAAS (renin-angiotensin-aldosteron system) and FGF23, 
lowers the proteinuria, and reduces vascular calcification and inflammatory processes. 
7.3. Indications for use 
Cinacalcet is indicated for the treatment of rHPT in patients on chronic dialysis and to treat 
persistent/recurrent HPT after PTx in these patients [49, 60]. Combined therapy with cinacalcet 
and active Vitamin D3 lowers PTH levels and improves Ca-P homeostasis in patients with renal 
HPT receiving chronic dialysis [35, 53]. There were also studies of cinacalcet in patients with 
CKD III and IV, showing a significant lowering of serum PTH and Ca, one of these was a 
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randomized double-blind controlled study by Chonchol et al. [61]. Yet cinacalcet was not 
approved by European authorities and the Food and Drug Administration (FDA) for this group 
of patients because of frequent occurrence of hypocalcemia in the treatment group as compared 
to placebo. 
Recent studies have shown promising outcomes after de novo therapy with cinacalcet in patients 
with persistent HPT after KTx [54, 62, 63]. Nevertheless cinacalcet is not approved for routine 
use in this group of patients [64]. 
Other indications for the use of cinacalcet are: 
 Cancer of the parathyroid glands [65] 
 PHPT and as a part of MEN1 syndrome when an operation is not possible [66, 67] 
 There are several described cases of treatment of familial hypocalciuric hypercalcemia 
[68]. 
7.4.  Adverse effects 
The most common adverse effects are those of the gastro-intestinal tract: nausea, vomiting and 
diarrhea, with mild to moderate intensity. Prevalence of nausea is reported as 10-43%, vomiting 
4.7-30%, diarrhea 0.9-19% [35, 53-55, 64, 69, 70]. Clinical trials have shown that cinacalcet had 
no severe side effects, resulting in low rate of therapy discontinuation due to this reason, 6% 
according to some authors [35]. 
Hypocalcemia is another side effect in chronic dialysis patients receiving cinacalcet, in most 
reports this effect is asymptomatic although clinically relevant [53, 70]. 
8. Study design 
In the present retrospective study the outcome of PTx in patients with or without cinacalcet 
treatment was analyzed. The emphasis was laid on the rate of perioperative, long-term 
cardiovascular and other complications, on the rate of recurrent and persistent HPT and on the 
renal graft function in transplanted patients. 
9. Methods 




Inclusion criteria Exclusion criteria 
Renal HPT pHPT 
Operation in 01.01.2008 – 01.02.2015 Other types of HPT (as part of hereditary 
syndrome e.g. MEN-syndrome) 
Operations in other hospitals 
Table 3: Inclusion/Exclusion criteria 
A hospital-based database of patients with all types of HPT who underwent surgical treatment in 
Charité Campus Virchow Clinic was originally set up in 1998 and was retrospectively screened 
for patients with renal HPT in 2008-2015. Other types of HPT were not included in the research. 
There were two retrospective cohorts of patients, a cohort receiving cinacalcet preoperatively, 
and the other group without cinacalcet. The decision to prescribe cinacalcet was taken by the 
attending nephrologists. The surgical team had no influence on that decision. 
There were few patients in the study who were operated on for persistent/recurrent HPT. 
Because of the small number of those patients (and lack of the exact data about the first 
operation) no separate analysis within that group was performed. The number of operations 
exceeded the number of patients due to reoperations. We used the term “case of HPT” and 
analyzed our study groups respective to the number of cases, not patients, when not explicitly 
noted otherwise. We did not include the cases of operations performed in other hospitals, 
whereas the operations for the recurrent disease performed in Charité were included and counted 
as independent cases. 
9.1.2. Follow-up (Surveillance) 
The above mentioned attending nephrologists treated the patients after discharge from hospital 
and performed the surveillance. They provided us on request (per fax, mail or e-mail) with most 
of the information on the follow-up as to 05.2015. Another source for the follow-up information 
was the European transplantation database “TBase” containing data on patients on the 
transplantation list. 
Data on survival, diagnosis/comorbidities, and laboratory values of patients were acquired from 
the above two sources in addition to the conventional medical records in SAP Program. 
9.2.  Patient cohort 
Standard demographic data: age, sex and age by the time of operation were routinely registered 
in all patients. 
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9.2.1. Medical treatment 
Patients referred to the Charité hospital for operation continued to receive cinacalcet when it was 
prescribed by their physician. Cinacalcet was stopped after the operation was performed. 
Hemodialysis was performed at usual intervals. 
9.2.2. Surgical treatment 
Patients were referred to the clinic by the attending nephrologists. Indication for the operation 
was a result of an interdisciplinary nephrological-surgical conference. 
All patients in both cohorts were operated on by the same surgical team. 
The standard surgical treatment was sPTx. 
A tPTx was performed in the following situations: 
- high risk of recurrent HPT in patients not listed to KTx, 
- intraoperative situation, when no suitable parathyroid tissue could be preserved (due to 
anatomical reasons). 
A subtotal PTx was a standard operative procedure for tHPT in the Charité Clinic. 
A neuromonitoring of the laryngeal recurrent nerve was performed in all cases. 
Cervical thymectomy was not routinely performed. Indication for this procedure was a missing 
parathyroid gland. 
Other surgical interventions were very rare and will be described individually. 
AT was not routinely performed.  
Simultaneous thyroid surgery was performed based on indication, either preoperatively or during 
the operation, or in search of missing parathyroid glands. The performed operations were hemi- 
and thyroidectomy, Dunhill-operation, subtotal resection and enucleating of nodes. The cases of 
simultaneously performed thyroid operations were separately documented and analyzed.  
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Figure 5: Different types of thyroid operations, image from: The surgical treatment of bilateral 
benign nodular goiter—balancing invasiveness with complications [71]. 
Resected tissue was pathologically processed and a histological confirmation of the parathyroid 
tissue was obtained. Cryopreservation was performed in all cases. 
The rate of surgical complications was registered, including bleeding and hematomas, wound 
infection and nerve damage.  
The duration of in-hospital stay after the operation was determined based on medical records. 
9.2.3. Outpatient treatment 
A long-term medical therapy was prescribed by attending nephrologists and was continued with 
required modifications during the in-hospital stay. 
Dialysis in respective patients was performed at usual intervals; the date of the first chronic 
dialysis session was registered. 
Stage of CKD and preoperative serum creatinin level were documented. Duration of dialysis in 
patients with transplanted kidneys, who were no longer susceptible to it, was registered. 
Referring nephrologists were performing surveillance including assessment of graft function 
after hospital discharge, corresponding data were obtained from the TBase, missing data were 
provided on request. 
9.2.4. Perioperative treatment 
Postoperative daily Ca-controls and a PTH control on the 1-st postoperative day were performed. 
In cases of symptomatic hypocalcemia, additional controls were performed. In cases with high 
Subtotal bilateral resection Dunhill operation Total thyroidectomy 
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postoperative PTH levels they were repeatedly controlled. With falling PTH levels the operation 
success was stated and standard surveillance was recommended. In cases of non-falling PTH 
levels an individual diagnostic and treatment protocol was developed. If a persistent 
hyperparathyroidism was present, diagnostic tests (PTH selective venous sampling, MIBI 
SPECT) were done. 
1000mg Ca was given orally three times a day. When the Ca level was falling on the following 
day, 2000mg or more were given orally. For most of the patients this regimen was sufficient, and 
for patients with Ca below 1.6 mmol/l and symptoms of tetany a parenteral substitution was 
indicated. Another factor stabilizing serum Ca was haemodialysis with a supplementation of Ca, 
which was the case in many of the patients. In addition, Vitamin D3 (calcitriol 0,5µg once a day) 
was administered. 
The discharge of patients depending on their serum Ca levels was possible only when those were 
stable in daily blood samples, defined as two non-falling Ca levels in 2 subsequent days under 
oral substitution. 
9.3. Study instruments 
9.3.1. Laboratory values 
The preoperative Ca and PTH level, as well as creatinin, AP (alkaline phosphatase), and P were 
measured using the routine laboratory technique in Charité Clinic. Reference ranges are 
presented in the table below. The surveillance of laboratory values was performed by external 
physicians and these were recalculated in SI units respectively. 
Laboratory test Measure units (SI) Reference ranges 
AP U/l 35-105 
Ca mmol/l 2.15-2.5 
Creatinin mg/dl 0.5-0.9 
P mmol/l 0.87-1.45 
PTH ng/l 14.9-56.9 
Table 4: Laboratory tests and reference range 
The following definitions for CKD staging were used: 
CKD V, or terminal CKD 
CKD IV or preterminal CKD 
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CKD II, III or compensated CKD 
CKD I termed in this report as “no kidney insufficiency” on the graphs. 
According to K/DOQI guidelines, in patients with terminal CKD target range of PTH was 
defined as 150-300 ng/l [34]. 
9.3.2. Ear-nose-throat specialist evaluation 
Each patient was evaluated by an independent ear-nose-throat (ENT) specialist before and after 
the operation. Vocal cord status was documented with special emphasis on transient/persistent 
palsy as a sign of laryngeal nerve trauma. If recurrent nerve palsy did not resolve within six 
months, it was defined as persistent. In cases of newly diagnosed recurrent nerve palsy the 
attending physicians were individually contacted and the patients were followed up by Charité 
phoniatric clinic. 
9.4. Statistical methods 
The data were analyzed with STATISTICA 7.0 software (Stat Soft Inc., USA). All numerical 
results are presented in means ± standard deviation (independent from normality of the 
distribution) and categorical results – as percentages. Numerical data were tested on normality 
with Kolmogorov-Smirnov test (K-S test). 
Normally distributed data was tested with an unpaired t-test after comparing the variances with 
Levin-test. In the analysis of nonparametric data in independent groups Kolmogorov-Smirnov 
test was used for continuous variables. Chi-square (χ2) test with Yates's correction or Kruskal-
Wallis H test was used for nominal variables. Nonparametric data in dependent groups were 
analyzed with Wilcoxon matched pair test. A Kaplan-Meier survival analysis with Log-Rank test 
for group comparison was performed. 
Statistical significance was defined by p<0.05. 
10. Results 
10.1. Demographic data 
The study included 191 patients resulting in 196 operations (cases). There were 80 cases (41%) 
with cinacalcet therapy. Basic population data are presented in the table below. 
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 With cinacalcet, n=80 No cinacalcet, n=116 
Sex 39 male /41 female (49/51%) 76 male /40 female (66/34%) 
Age (mean±SD) 51.2±13.3 years 51.5±12.7 years 
Table 5: Demographic data 
10.2. Chronic Kidney Disease 
The diagnoses leading to CKD (counted per capita, not by case numbers) are listed in the table 
below in descending order: 
  Count Percent  

























IgA Nephropathy 11 6% 




Other 56 29%  
Table 6: Diagnoses leading to CKD 
The CKD stage at the moment of operation was distributed as follows: 
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Graph 1: Diagram of renal insufficiency status by the time of PTx 
The patients without renal insufficiency all had a functioning kidney graft. They constitute a 
group with renal HPT even after the KTx. 
There were 60% of transplanted patients in the study group as to May 2015 (counted per capita): 
 
Graph 2: Diagram of KTx status in patients related to cinacalcet therapy 
The PTx operation could be performed either before or after the KTx. 
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The status of graft function is presented below (only transplanted patients are included). Patients 
are sorted in groups related to cinacalcet therapy and according to the order of operations: those 
undergoing PTx before KTx are in the lower row. 
 
Graph 3: Diagram of the CKD stage in transplanted patients related to the time of PTx and 
cinacalcet therapy. 
There were six patients with more than one KTx, detailed data on chronological order of their 










Graft function at 





Graft function as 
to 2015 
1/w/47 1985 1987 1997 No 2011  No 
2/m/50 1983 1990 2000 No 2014  No 
3/w/49 1984 - - No 2009 2010 Yes 
4/m/69 2005 - - No 2009 2010 Pat. deceased 
5/m/40 1997 - - No 2012 2014 Yes 
6/w/51 1998 - - No 2009 2014 Yes 
Table 7: Detailed data on patients with more than one KTx 
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10.3. Comorbidities 
The study patients had a high rate of multimorbidity. The following chronic diseases were 
registered: 
Diagnosis With cinacalcet Without cinacalcet 
aHT 100% 100% 
DM Type I 4% 3% 
DM Type II 24% 22% 
Adipositas 9% 13% 
Ischemic heart disease 30% 27% 
Table 8: Major comorbidities in the study population 
10.4. Medical treatment 
The prevalence of cinacalcet therapy was 41%, with no missing data. 
In 82% of the cases patients were receiving phosphate binders, in 13% this therapy wasn’t 
applied, in 5% of the cases the data were missing. The diagram represents the type of phosphate 
binders used in the whole group. 
 
Graph 4: Diagram of distribution of phosphate binders in the study group. 
In 86% of the cases active vitamin D3 analogues were given, 8% didn’t receive this treatment, in 
6% the data were missing. 
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The preoperative use of phosphate binders and vitamin D3 analogues in the groups relative to 
cinacalcet is presented below. The distribution did not differ between the two groups (χ2 test, 
p=0.7512). 
 Preoperative cinacalcet No cinacalcet 
Phosphate binders 66 86 
Vitamin D 70 98 
Table 9: Data on medical therapy, presented in case numbers.  
10.5. Operative data 
10.5.1. Operations 
89% of all cases were primary operations for renal HPT; operations for recurrent HPT were 
performed in 11% of cases. The distribution in the two study groups was as follows: 
 
Graph 5: PTx indications in groups with/without cinacalcet. 
Operations for recurrent HPT were performed in 20 cases on 19 patients. Five patients were 
initially operated on in Charité Clinic and 15 patients had their first operations in other hospitals. 
One patient was operated twice for recurrent HPT within the study time range (2nd reoperation). 
Time interval between the first operation and reoperation was 915±771 days (mean±SD), range 
215 to 1902. 
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The distribution of all types of operations by years is shown in the bar chart below, divided in 
two study groups respectively. There is a trend of increased cinacalcet usage (Graph 6 below). 
The proportion of patients receiving cinacalcet preoperatively shows a statistically significant 
difference among the observation years (Kruskall-Wallis H test p<0.0001). 
 
Graph 6: Histogram of number of operations sorted by years and cinacalcet therapy. 
The operations performed were sPTx in 70% of cases (n=138), and tPTx in 20% of cases (n=38), 
the distribution in the study groups is presented below. The remaining 10% of operations were 
performed for recurrent HPT. A multigroup comparison didn´t detect a statistical significance in 
distribution of operation types (Kruskall-Wallis H test, p=0.0611). 
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Graph 7: Types of operations related to cinacalcet therapy. 
The type of operation for recurrent HPT was determined individually based on preoperative 
imaging studies. Among those two thoracoscopies for mediastinal adenomas were performed 
(both in the group without cinacalcet). 
Simultaneous thyroid surgery was performed in 47% of cases; the types of operations are 
presented below (Graph 8). There was no statistical significance in their distribution between the 




Graph 8, 9: Prevalence of simultaneous thyroid operations. 
Indications for simultaneous thyroid surgery were toxic adenoma (n=1), multifocal toxicity (n= 
2), potentially malignant thyroid nodules (n= 18), multinodular nontoxic goiter (n=56). Another 
indication for hemithyroidectomy was a missing parathyroid gland on the corresponding side and 
suspicion of intrathyroidal parathyroid glands (n=12).  
In six patients thyroid cancer was histologically confirmed. There were four patients with 
papillary thyroid cancer and one with medullary thyroid cancer. One patient with 
hemithyroidectomy and no cancer at the time of PTx some years later developed cervical lymph 
node metastasis (adenocarcinoma of unknown origin). 
Operation time did not differ between the two study groups, 126±44 vs. 136±39 minutes 




Graph 10: Operation time (in minutes) related to cinacalcet therapy. 
Operation time in case of simultaneous thyroid surgery was higher compared to PTx alone, with 
means of 156.3 and 109.5 minutes respectively (p=0.02, t-test). 
Operation time related to the type of parathyroid operation and simultaneous thyroid operation is 
presented below: 
 
Graph 11: Operation time related to PTx type and simultaneous thyroid operation. 
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10.5.2. Replantation of cryopreserved tissue 
Routine cryopreservation of PTG tissue was performed in all cases with a 0% rate of replantation 
during the study period. 
10.5.3. Duration of (in-)hospital stay 
Mean duration of in-hospital stay in our study was 7.0 days, similar in both groups (7.0 vs. 7.1 
with/without cinacalcet, p>0.1, K-S test). Comparing the mean values in years a decreasing trend 
could be observed (presented as an interquartile range graph, year 2015 omitted because of only 
three performed operations):  
 
Graph 12: Duration of in-hospital stay, median annual values (2008-2014). 
10.6. Surgical complications 
There were five recurrent nerve palsies, resulting in 5/196=2.6% complication rate. One case of 










1/w/31 Permanent Recurrent operation Hemithyroidectomy Yes 
2/w/38 Temporary sPTx Thyreoidectomy No 
3/w/65 Temporary sPTx None No 
4/m/34 Temporary sPTx Hemithyroidectomy Yes 
5/m/26 Temporary sPTx None No 
Table 10: Detailed data about patients with postoperative recurrent nerve palsy. 
Reoperation rate due to wound complications was 3/196 =1.5%, there were two wound 
hematomas and one case of wound infection requiring revision operation. 
The eight patients with high postoperative PTH levels ≥300ng/l (K/DOQI cut-off) were analyzed 
separately under the assumption of persistent HPT.  
- Patients No. 1 and 4 have shown a reduction of PTH levels in laboratory controls by 
hospital discharge thus confirming the efficacy of surgical treatment. 
- In patient No. 2 and 3 controls at discharge and two years after the operation respectively 
showed acceptable PTH levels. 
- In patient No. 5 only 3 PTG were localized during the operation, and these were 
completely removed, and a hemithyroidectomy was performed, 1-year follow-up was not 
reached. 
- Patient 6 was operated for recurrent HPT (initial OP in another hospital). During the neck 
exploration no PTG was found. 
- Patient No. 7 was operated seven months after the initial OP for persistent rHPT. Initially a 
sPTx with a subtotal hemithyroidectomy was performed. During reoperation no additional 
PTG were found and a hemithyroidectomy on the other side was performed. One-year 
control showed low PTH level. 
- Patient No. 8 had a supernumerary PTG in the neck, which was resected during a 
reoperation on the third postoperative day. 
























1/w/44 2009 537.0 366 83   No 
2/w/70 2011 545.0 374 199   Unknown 
3/w/53 2012 718.2 399 440 No data 161.5 No 
4/m/50 2008 491 406 5   Yes 
5/w/45 2014  415.5 326.8 No data  No 
6/m/68 2014 957.2 851 851 No data  Unknown 
7/m/54 2008 No data 440 382 6 5 No 
8/m/38 2011 1241 300 12 8.3 14.7 No 
Table 11: Data on patients with high postoperative PTH levels. 
Persistent HPT was thus diagnosed in four cases (PTH at discharge >300ng/l).  
There was one cardiovascular event in the postoperative period (group without cinacalcet): atrial 
fibrillation for a period of six hours, which was medically corrected. 
There was no perioperative mortality; all patients were discharged from hospital. 
10.7. Perioperative Ca homeostasis 
The preoperative serum Ca level was significantly lower in the cinacalcet group, 2.28±0.23 vs. 
2.41±0.23 (p=0.0002, t-test). 
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Graph 13: Preoperative serum Ca levels related to cinacalcet therapy. 
The lowest postoperative serum Ca levels were not significantly different in the two groups, 
1.89±0.30 vs. 1.92±0.30 (p=0.40, t-test). 
 
Graph 14: Lowest postoperative serum Ca levels related to cinacalcet therapy. 
A mean number of 2-4 patients per year had symptomatic hypocalcemia after the operation with 
serum Ca < 1.6mmol/l (no statistical significance in Ca levels, K-S test p>0.10) 
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Graph 15: Number of patients with symptomatic hypocalcemia in both study groups by years. 
Ca levels at discharge did not differ in the two study groups, 2.12±0.30 mmol/l with cinacalcet 
and 2.12 ±0.27 mmol/l without it (p=0.90, t-test). 
 
Graph 16: Serum Ca levels at discharge related to cinacalcet therapy. 
10.8. Perioperative PTH levels 
The study groups did not differ regarding preoperative PTH levels, having mean values of 755 
and 742ng/l with and without cinacalcet respectively (p>0.10 K-S test). The values are presented 
as a normal probability plot for better visualization, although normal distribution is not 
confirmed (K-S test for normality p<0.01). 
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Graph 17: Preoperative PTH levels related to cinacalcet therapy. 
Controls of PTH on the 1-st postoperative day showed no significant difference between groups, 
with mean values of 49.8 and 42.2ng/l with and without cinacalcet respectively (p>0.10 K-S 
test). The values are presented as a normal probability plot (K-S test for normality is p<0.01). 
 
Graph 18: Postoperative PTH levels related to cinacalcet therapy. 
In patients with high postoperative PTH levels additional PTH control at the time of hospital 
discharge was performed. There were four patients with PTH levels >300ng/l (K/DOQI cut-off 
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level), three of them (1.5%) received cinacalcet preoperatively. In these patients, persistent HPT 
was confirmed. 
10.9. Alkaline phosphatase preoperative data 
Alkaline phosphatase levels were measured once before the operation, alkaline phosphatase level 
at discharge was not documented. In groups of patients with and without cinacalcet alkaline 
phosphatase levels did not significantly differ (p0.10, K-S test). Data is presented as box and 
whiskers plot for a better visualization. 
  
Graph 19: Alkaline phosphatase levels preoperatively related to cinacalcet therapy. 
10.10. One-year follow-up data 
Mean follow-up time was 48.4±25.2 months (4 to 88), 39.7±22.6 (4 to 86) with cinacalcet and 
54.4±25.3 (4 to 88) without cinacalcet. Therefore, it was significantly shorter in the cinacalcet 
group (p<0.001, K-S test). 
10.10.1. Ca levels at 1-year controls 
Ca control one year after the operation showed no significant differences in the two study 
groups, 2.26±0.25 in the group receiving cinacalcet preoperatively and 2.24±0.25 in the other 
one (p=0.67, t-test). 
45 
 
Graph 20: Ca levels at 1-year controls related to preoperative cinacalcet therapy. 
10.10.2. PTH levels at 1-year controls 
PTH one year after the operation  showed no significant differences in the two study groups, 
mean values were 26.9 ng/l in the group receiving cinacalcet preoperatively and 42.1 ng/l in the 
other group (p>0.10, K-S test). Values are presented as a normal probability plot (K-S test for 
normality is p<0.01). The marked case ( ) will be discussed separately (female patient W.). 
 
Graph 21: PTH levels at 1-year controls related to preoperative cinacalcet therapy. 
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We separately observed the PTH levels in patients with extremely high PTH levels before the 
operation (>2000), because a high risk of recurrence was assumed. It was noticed that the PTH 













PTH 1 year 
after 
operation 
Death as to 
05.2015 
1/w/69 2013 2017 124 124 24 No 
2/m/26 2009 2085 39 39 No data unknown 
3/w/64 2012 2164 13 3 No data unknown 
4/w/43 2011 2204 10 10 56 No 
5/w/51 2009 2255 24 12 6 No 
6/m/36 2010 2967 9 9 7 No 
7/w/47 2011 5000 281 196 No data Yes 
Table 12: Data on patients with extremely high preoperative PTH levels. 
The single patient, who had undergone a hemithyroidectomy and one-sided PTx in 2011 with 
acceptable levels of PTH at discharge, had high PTH levels one year after operation. A recurrent 





















72 01.2011 209 146 196 480.8 
No 
74 11.2012 587 10 10 39.6 
Table 13: Detailed description of the patient with persistent HPT one year after the initial 
operation. 
10.11. AP levels at 1-year controls 
AP levels of patients in the two study groups at 1-year controls did not show a statistically 
significant difference (p0.10, K-S test), a box plot is presented below. 
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Graph 22: Alkaline phosphatase levels at 1-year controls related to preoperative cinacalcet 
therapy. 
10.11.1. Graft function one year after PTx 
Nephrologists in the Charité clinic recommend performing PTx before KTx to avoid possible 
deterioration of kidney graft function. The proportion of patients in whom the parathyroidectomy 
was performed before kidney transplantation, or vice versa is shown in the figure below. 
 
Graph 23: Proportion of patients undergoing PTx before and after KTx during the study period 
Prevalence of preoperative cinacalcet therapy between these groups did not differ significantly 
(χ2 test, p=0.7725). 
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Some of the patients with a kidney graft (KTx before PTx) had a good graft function and CKD 
stages I, II, III at the time of the PTx (22/47 transplanted patients). Creatinin levels before the 
PTx and at one-year control were compared in patients with kidney grafts and compensated 
kidney function at the moment of operation. There were no statistically significant differences in 
creatinine levels one year after the PTx neither in the whole group nor in the subgroups 
with/without cinacalcet (Wilcoxon test p=0.11 for whole cohort, p=0.14 with cinacalcet, p=0.33 
without cinacalcet). 
 
Graph 24: Creatinine levels in patients with kidney grafts and good graft function by the time of 
PTx and at one year controls. 
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Graph 25: Creatinine levels in patients with kidney graft and good graft function by the time of 
PTx and at one year controls related to cinacalcet therapy preoperatively. 
10.12. Mortality rates (as to 31.05.2015). 
The follow-up data for the present study were obtained in close cooperation with the referring 
physicians. Nevertheless a significant number of patients (46 of 191 i.e. 24%) were lost to follow 
up. They were international patients with missing contact data, patients who relocated and/or 
changed the referring physicians, and those who didn’t show up for the termed controls due to 
unknown reasons. 
 
Graph 26: Diagram of mortality rates as to 05.2015 related to cinacalcet therapy preoperatively. 
Mortality rates did not differ in the two study groups (12/52 vs. 14/72 with vs. without 
cinacalcet; p=0.68, χ² test). 
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Log-Rank Test p=0.10928 (n.s.)
Graph 27: Kaplan-Meier survival analysis for the two study groups. 
A Kaplan-Meier survival analysis with Log-Rank test comparing the two study groups did not 
show a statistical significance (p= 0.10928). 
10.13. Cardiovascular events (as to 31.05.2015) 
The following table shows the prevalence of cardiovascular events after PTx in both study 
groups. The precise moment of each event was not limited to the time of observation, but the cut-
off point was the end of the study. The comparison has shown no significant statistical difference 
between the groups. 
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 With cinacalcet Without cinacalcet Statistical significance 
(χ²-test) 
Myocardial infarction 13% 18% Non significant 
PTA/Bypass 13% 22% Non significant 
Peripheral  Bypass 9% 12% Non significant 
Stroke 13% 10% Non significant 
Table 14: Cardiovascular events as to 05.2015 related to cinacalcet therapy. 
11. Discussion 
Cinacalcet is a relatively new drug, introduced to market in 2004, but to date there is a 
substantial amount of experience of using it in specialized clinics and nephrological centers. 
Most of the publications regarding therapy with cinacalcet are focused on the changes in 
treatment of renal HPT in patients on chronic dialysis after the introduction of a completely new 
active agent. The present study is focused on patients who received cinacalcet and underwent 
surgical treatment for renal HPT.  
Published data suggests that cinacalcet effect in renal HPT is limited in time, and HPT 
recurrence also happens in patients receiving medical treatment preoperatively [33, 59]. In our 
study all patients in the cinacalcet group had high levels of HPT and indications for PTx. Ten out 
of 20 patients undergoing surgical treatment for recurrent disease were treated with cinacalcet 
preoperatively. 
The main result of the undertaken retrospective study is that no significant differences in the 
intra- and postoperative period in patients with and without cinacalcet therapy have been 
detected. That implies a similar risk/benefit ratio for patients undergoing surgical treatment of 
renal HPT both after prior treatment with cinacalcet and without it. 
The rate of cardiovascular events and mortality by the end of the surveillance period was not 
significantly different in the study groups. 
There were no perioperative deaths and no life-threatening complications. 
The rate of recurrent HPT was 5/196=2.6% within the study period and was similar in both 
groups. The rate of persistent HPT was 4/196=2.0% with nearly all patients in the cinacalcet 
group (3/196= 1.5%). 
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Kidney transplanted patients with good graft function at the time of PTx showed no significant 
differences in creatinine levels one year postoperatively.  
The study has revealed practically equivalent retrospective outcomes of surgical treatment for 
renal HPT, either after the therapy with cinacalcet or without it. 
There are currently only few other publications comparing perioperative data on patients with 
and without cinacalcet undergoing surgical treatment. 
Oltmann et al. studied the perioperative course of 36 patients with end stage renal disease treated 
by parathyroidectomy. [72] Many preoperative parameters (Ca, P, PTH, pre- and postOP, 
surveillance, all-cause survival) were observed to have influence on the outcome of patients with 
sHPT undergoing PTx. 50% of patients were treated with cinacalcet preoperatively but there was 
no analysis of the outcome related to cinacalcet therapy. 
In a second report from Coulston et al. [73] cinacalcet therapy was applied to 16.5% of patients 
receiving parathyroidectomy, but again, no separate analysis of this parameter was performed 
either. 
In a recent retrospective  research [74] a decrease in numbers of parathyroidectomy for tHPT 
since 2004 is stated, which coincides with the introduction of cinacalcet to the market.  
11.1. Characteristics of the study group 
The retrospective analysis was performed using a single-centre database. The observed time 
range was 2008 - 2015, whereas cinacalcet has been available since 2004. This made it possible 
to include patients who were treated with cinacalcet and showed refractory high PTH levels. 
They were compared to the patients who received no cinacalcet but were operated on at the same 
period of time. 
The study population comprises patients who were operated on for renal HPT. We included 
patients either with sHPT, or with tHPT. Mean age (51.4±12.9, range 12 to 81 years) and number 
of comorbidities in the study group differ much from the general population of chronic dialysis 
patients, thus, the rate of diabetic nephropathy alone was 16% compared to 35% in the combined 
group of German chronic dialysis patients [26]. The overall rate of KTx in the study group was 
60%, which can be regarded as an indirect sign for younger age and overall better ASA risk 
class. 
The two study cohorts were comparable in basic demographic data - age, sex and rate of 
comorbidities (Table 5, table 8). The number of patients in the group receiving cinacalcet was 
smaller (80 vs. 116), although the histogram (Graph 6) shows a rising number of patients in the 
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cinacalcet group. There are correlating published data: in a study from 2010 [73] the rate of 
patients receiving cinacalcet was 16.5%, in 2015 [72] 50%. 
The study groups had similar proportions of primary operations for renal HPT and operations for 
recurrent renal HPT, the rate of recurrent operations was 13% vs. 9% (Graph 5). 
The patient population represents a multimorbid group, most of them receiving chronic dialysis 
for a long period of time. At the time of operation most patients had terminal CKD and were on 
dialysis. In the group without cinacalcet there were more patients with sufficient renal function 
(16% vs. 9%), which can be accounted for two reasons: first, cinacalcet is not allowed in CKD 
III-IV; second, (p>0.10 K-S test)  
 in patients with transplanted kidney and good graft function cinacalcet can be prescribed for 
treatment of HPT only after individual clinical evaluation and confirmation from the insurance 
company. 
11.2.  Operative data 
11.2.1. Types of operations 
There were two types of operations for renal HPT in our study population: sPTx being a standard 
procedure (n=138) and tPTx without AT (n=38) performed in patients with high risk of recurrent 
disease and due to anatomical reasons. Although in the K/DOQI guidelines [34] the three 
operations, tPTx, sPTx, and tPTx with AT are described as equally effective in view of the 
outcome, the choice of the operation can be left to the surgeon. In a retrospective study (n=606) 
by R. Schneider et al. [40] different types of operations for renal HPT were compared. The most 
common operation in that study was a tPTx with AT (504 of 606) as the standard procedure in 
the institution. The sPTx was performed in 21/606 cases as the equivalent procedure before 
1991. The rate of persistant HPT requiring reoperation was not significant as well no 
autotransplantation of cryopreserved parathyroid tissue was necessary. A tPTx without AT was 
performed in 32/606 cases, and there were no reimplantations in that subgroup, as well as no 
adynamic bone disease. The authors conclude that tPTx without AT may be accepted as a routine 
operation and the existing practice of routine cryopreservation should be critically evaluated, 
although the risk of adynamic bone disease should be kept in mind. 
There was a study comparing tPTx with tPTx+AT+thymectomy by K.Schlosser [75]. None of 
the patients with tPTx only received a delayed AT. The need for routine cryopreservation of 
parathyroid tissue was put under the question, and further studies were anticipated. 
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In our study groups special parameters of renal bone disease could not be analyzed, but no 
clinical symptoms, like bone pain and fractures, were reported from the referring physicians and 
alkaline phosphatase levels were not elevated during the follow-up (Graph 22). 
In a previous retrospective study performed at our clinic 33 kidney transplanted patients with 
tHPT have undergone either sPTX or tPTX without AT. A relatively high rate of HPT 
persistence or recurrence (5/16=31%) was observed in the sPTx group compared to 0/17 in the 
tPTx group. No symptomatic hypoparathyroidism or hypocalcemia was observed under medical 
treatment in both groups [45]. 
A meta-analysis was performed to compare the efficacy of sPTX and tPTX with AT related to 
rate of recurrent HPT, both retrospective and prospective studies were included [76]. Authors 
state both procedures to be equally effective and to have similar recurrence rates. Neither of the 
studies included in this meta-analysis, nor in any other publication have compared outcomes of 
different operations related to cinacalcet therapy preoperatively. 
Based on our study results and on published data, the two operative procedures (sPTX and tPTX) 
are comparable regarding outcomes, complications and recurrence. 
There was a similar proportion of operations for recurrent HPT in the study groups, 5% and 6% 
with/without cinacalcet respectively (Graph 7). Operations for recurrent disease are technically 
more challenging, due to postoperative scarring with fibrosis, abnormal anatomy and difficulties 
in both preoperative imaging and intraoperative localization of parathyroid tissue. In addition to 
cervical operations, two thoracoscopic removals of ectopic PT glands were performed (both in 
the group without cinacalcet). 
11.2.2. Operating time 
The operating time did not differ significantly between the study groups (means 126 and 136 
minutes), but was significantly longer in case of simultaneous thyroid operation (156.3 vs.109.5 
min). Simultaneous thyroid operations were performed in 47% of the cases (Graph 10, graph 11). 
A report by L.Kuo [48] with 898 retrospectively reviewed operations shows a mean operative 
time of 133 and 120 min in groups of tPTx and sPTx respectively. The rate of simultaneous 
thyroid operations was 9.2% but the operating time in those cases was not separately analyzed. 
So overall, the operation time was within the expected range compared to the literature. 
The overall high rate of thyroid disease [71]  is one reason for the high rate of simultaneous 
thyroid operations. An additional indication for thyroid resection is presumed intrathyroidal 
parathyroid gland in case of a missing gland. In 12 of 196 (6%) of cases one of the PTG could 
not be found, so in 7/12 of these cases a simultaneous thyroid operation was performed. 
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11.2.3. Surgical complications 
The rate of complications was 2.6% (5/196) for recurrent laryngeal nerve palsies, 0.5% (1 case) 
was permanent (Table 10). This patient had a redo operation for recurrent rHPT. In literature the 
overall reported rate of temporary laryngeal nerve palsy in operations for rHPT was 5.4% by 
Schneider et al. [40], 11.6% by Schlosser et al. [38], with 1.1% and 0% of permanent palsies 
respectively. Probably, the use of intraoperative neuromonitoring and the fact that only few and 
very experienced surgeons performed the operations led to the relatively low rate of recurrent 
laryngeal nerve palsies. Notably, 1% of patients had preoperative laryngeal nerve palsies 
detected on the preoperative ENT check. This underlines the importance of thorough 
examination of the vocal cords routinely before and after the operation. 
A study by Shih [46] reports 14.9% (14/94) postoperative complications: combined neck 
hematomas and vocal cord palsy, unfortunately without further specification. In this study ENT 
assessment either before or after operation was not performed as a routine procedure, only a 
clinical assessment was stated. 
In addition, 1.5% wound complications were recorded, 1% of them being hematomas and 0.5% 
wound infections requiring revision. Again, there were no significant differences between the 
study groups. No previous reports on that issue have been published so far.  
The rate of postoperative bleeding was reported to be 0.45% by L.Kuo [48]. Schneider et al. [40] 
report 1% of bleeding rate, 1.3% of wound infection, our data being similar to both studies; the 
overall complication rate in the latter retrospective analysis [40] was 7.9% (including cardiac, 
neurologic and other). 
11.2.4. Duration of hospital stay 
In recent years a tight cooperation of outpatient nephrologists and dialysis centers has allowed 
earlier discharge of patients once the Ca levels were defined as stable (not decreasing in two 
consequent blood tests) under oral Calcium- and Vitamin D3 supply (Graph 12). The 
preoperative use of cinacalcet had no influence on the hospital stay in our patients. 
Compared to the study by L.Kuo [48] with a mean of four days of in-hospital stay, our study has 
shown a longer in-hospital stay, discharge conditions were not documented by Kuo. The study 
by Shih [46] reports a mean duration of in-hospital stay of 6 and 9 days in tPTx and sPTx groups 
respectively, discharge conditions were defined as stabilized normal serum Ca levels. These 
numbers were comparable to the results at the first years of this study. 
11.3.  Perioperative PTH and Ca homeostasis 
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The two study groups had similar preoperative PTH levels with means of 755 and 742 ng/ml 
(Graph 17). At the same time the preoperative serum Ca levels differed significantly, being 
lower in the cinacalcet group, 2.28±0.23 vs. 2.41±0.23 mmol/l (p=0.0002, t-test) presumably 
reflecting the efficacy of cinacalcet on Ca homeostasis, but not on PTH levels (Graph 13). The 
study of medically treated patients with renal HPT has shown significantly lower Ca levels 
compared to placebo-controls [53]. 
The postoperative minimal Ca levels and Ca levels at discharge did not differ significantly 
between the groups (Graph 14, graph 16). The use of cinacalcet did not affect Ca homeostasis in 
postoperative patients. 
There was no statistical significance in postoperative PTH levels between the groups (Graph 18). 
High PTH levels were recorded in some patients directly after the operation, and an additional 
laboratory control was performed before discharge. There were four cases (2%) with persistent 
HPT (PTH>300 ng/l) at discharge. In published studies with comparable groups of patients a 
similar rate of persistent HPT was reported with 0.83% and 1.4% [38, 40]. A higher rate of 3% 
and 3.1% [44, 72] was reported in a relatively small group of patients n=36 [72] published in 
2002 and including less radical operation types (removal of only 1, 2 or 3 parathyroid glands) 
[44]. At present, no study has separately compared Ca and PTH levels before and after operation 
related to preoperative cinacalcet therapy. 
11.4.  PTH and Ca one year postoperatively, recurrent HPT 
The levels of Ca and PTH did not differ significantly between the study groups at 1-year control. 
Within 1 year after the operation only one patient (1/196 = 0.51%) had a reoperation in Charité 
Clinic due to high PTH and Ca levels (Table 13). The cumulative recurrence rate is increasing 
with a longer follow-up. There were a total of five (2.6%) reoperations for recurrent HPT in the 
clinic.  
In studies reporting surgical treatment of renal HPT the following recurrence rates can be  
encountered: 3.5% (tPTx without AT) [73], 5.3% (tPTX+AT), 9.5% (sPTX) 6.1% (incomplete 
PTx) [40], 5.8% (sPTx and tPTx with AT) [44], 11.7% (tPTx without AT) [46], 0% (tPTx), 31% 
(sPTx) [45]. These rates are difficult to compare due to differences in study conditions like 
kidney function, different types of operations, follow-up time and others. 
In the German guidelines, a remnant of about 60 to 80 mg is recommended, although a correct 
estimation intraoperatively might be challenging [45]. Experience of the surgeon and correct 
identification of supernumerary glands are believed to be main factors predisposing to recurrent 
HPT [28, 42]. 
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In the group of patients without KTx the driving factors of mineral metabolism disturbances are 
ongoing and a higher rate of recurrent HPT disease is expected [32, 41]. 
In addition, the definition of recurrent disease differs between studies, so the rate of recurrent 
HPT in the study by C.Dotzenrath [44] was 12.2%, whereas the reoperation rate was only 3.5%, 
other studies report only reoperation rates.  
11.5. Kidney transplantation status and graft function 
11.5.1. KTx status 
Both study groups consisted predominantly of patients with terminal CKD, 91% in the group 
receiving cinacalcet, and 84% in the other. There were 3% of patients with preterminal CKD 
(stage IV) in the group without cinacalcet – those undergoing elective PTx before KTx from a 
living donor (Graph 1). Cinacalcet in CKD IV could only be administered as off-label use. 
Patients with CKD I-III in both groups were those after KTx with good to moderate graft 
function, but with persisting renal HPT. Patients of this subgroup receiving cinacalcet underwent 
individual decisions for treatment after interdisciplinary discussions. As to 2015 there were more 
transplanted patients in the group without cinacalcet - 64% vs. 54% (Graph 2). There is one 
explanation for that fact: a surgical-nephrological conference was more likely to select a PTx 
rather than cinacalcet as treatment for renal HPT in a patient with sHPT resistant to medical 
treatment, once the chances for receiving a kidney transplant were high. 
This statement is further supported by a subgroup analysis of patients with transplanted kidneys: 
there were 17 patients undergoing PTx before KTx in the cinacalcet group, and 37 patients 
undergoing PTx before KTx not receiving cinacalcet. 
There were similar rates of terminal CKD among patients operated for renal HPT who had KTx 
in the medical history: in both study groups 14/21 and 11/26 with/without cinacalcet respectively 
(Graph 3). 
11.5.2. Graft function 
A literature review (2010) by C.Dotzenrath [37] discusses the risk of decreased graft function 
following parathyroidectomy: some authors reported worsening of graft function after the 
operation [32, 77], whereas others didn’t [38]. From previous experience in our own patients, we 
prefer to perform the parathyroidectomy beforehand. In our study 54 vs. 16 patients have 
undergone KTx after the PTx operation (Graph 23). 
Creatinine levels in patients with tHPT (i.e. those with a functioning kidney transplant, defined 
as CKD I-III, n=22) were analyzed before PTx and one year after operation. There were no 
significant differences neither in the whole group, nor in the subgroups related to cinacalcet 
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therapy (Graph 24, graph 25). We did not analyse immunological markers in all patients. 
Therefore, we are not able to detect immunological changes. Creatinine is only a gross marker of 
graft function.  
11.6. Cardiovascular events and mortality 
The study group had a high rate of comorbidities with an overall high rate of mortality due to 
cardiovascular and other causes but not the operation itself. Mortality was not a primary end 
point in the present study. 
The observed cumulative rate of cardiovascular events over the whole study period was higher in 
the group without cinacalcet (Table 11), although not statistically significant.  
No perioperative mortality was registered in the study group; all patients were discharged from 
hospital. These data are comparable with the perioperative mortality reported in a large 
American retrospective study with a similar patient population being 2/898=0.22% within 30 
days after PTx [48]. 
As to 2015 there was a 15% and 12% mortality rate in the groups with/without cinacalcet 
(p=0.68), accounting for an overall mortality of app. 3.3% per year of surveillance. At the same 
time exact data were missing in 26% of the patients (Graph 26, graph 27). 
Yearly mortality rate in the cumulative population of chronic dialysis patients in Germany was 
18% as to 2005 [37], and up to 40% according to American MediCare data from 1999 [43]. Our 
data are not comparable due to the relatively better overall condition of our patients. Especially 
the high proportion of patients undergoing KTx after PTx shows a positive selection for elective 
surgery combined with younger age. 
An American study of chronic dialysis patients undergoing parathyroid surgery reports a 
mortality rate of 5.3% per year (8/36, mean surveillance 54 months) [72]. A British study by 
Coulson [73] reports a mortality rate of 7.7% per year in a similar patient population, both 
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